What is Asymchem Laboratories Tianjin Co EV-to-EBITDA?
Asymchem Laboratories Tianjin CoASLTY 72 EV-to-EBITDA is 19.33 as of Jul. 06, 2026, which is 46% below its 10-year median of 35.55. GuruFocus rates ASLTY with a GF Score™ of 72/100 and a GF Value™ of $4.63 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 393 Biotechnology companies, Asymchem Laboratories Tianjin Co ranks worse than 78.88% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Asymchem Laboratories Tianjin Co's enterprise value is $3,495.1 Mil.
Asymchem Laboratories Tianjin Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $180.8 Mil. Therefore, Asymchem Laboratories Tianjin Co's EV-to-EBITDA for today is 19.33.
The historical rank and industry rank for Asymchem Laboratories Tianjin Co's EV-to-EBITDA or its related term are showing as below:
ASLTY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.26 Med: 35.55 Max: 201.7
Current: 39.67
During the past 13 years, the highest EV-to-EBITDA of Asymchem Laboratories Tianjin Co was 201.70. The lowest was 7.26. And the median was 35.55.
ASLTY's EV-to-EBITDA is ranked worse than 78.88% of 393
companies
in the Biotechnology industry
Industry Median: 13.33
vs ASLTY: 39.67
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Asymchem Laboratories Tianjin Co (OTCPK:ASLTY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Asymchem Laboratories Tianjin Co's PE Ratio (TTM) for today is calculated as:
Asymchem Laboratories Tianjin Co's share price for today is $6.37.
Asymchem Laboratories Tianjin Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.221.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co EV-to-EBITDA Chart
ASLTY vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Asymchem Laboratories Tianjin Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asymchem Laboratories Tianjin Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Asymchem Laboratories Tianjin Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Asymchem Laboratories Tianjin Co's EV-to-EBITDA falls into.
Asymchem Laboratories Tianjin Co's current Enterprise Value is $3,495.1 Mil.
Asymchem Laboratories Tianjin Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $180.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co (ASLTY) has a EV-to-EBITDA of 19.33 as of Jul. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Asymchem Laboratories Tianjin Co. This is 46% below median its historical median of 35.55. Over the past decade, Asymchem Laboratories Tianjin Co's EV-to-EBITDA has ranged from 7.26 to 201.70. According to the industry distribution chart, Asymchem Laboratories Tianjin Co ranks #310 out of 393 companies in the Biotechnology industry, placing it in the top 78.9%.
Is Asymchem Laboratories Tianjin Co's EV-to-EBITDA too high?
Asymchem Laboratories Tianjin Co's current EV-to-EBITDA of 19.33 is 46% below median its 10-year median of 35.55. Over the past 10 years, this metric has ranged from a low of 7.26 to a high of 201.70. The Biotechnology industry median EV-to-EBITDA is 13.33. Asymchem Laboratories Tianjin Co's value of 19.33 is 45% above this industry median. Based on the distribution chart, Asymchem Laboratories Tianjin Co ranks #310 out of 393 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Asymchem Laboratories Tianjin Co has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asymchem Laboratories Tianjin Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Asymchem Laboratories Tianjin Co ranks #310 out of 393 companies for EV-to-EBITDA. This places Asymchem Laboratories Tianjin Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.33. Asymchem Laboratories Tianjin Co's value of 19.33 is 45% above this benchmark. Historically, Asymchem Laboratories Tianjin Co's own EV-to-EBITDA has ranged from 7.26 to 201.70 over the past decade. While the company's 10-year median is 35.55 vs. the industry median of 13.33, Asymchem Laboratories Tianjin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.33, based on 393 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asymchem Laboratories Tianjin Co's current EV-to-EBITDA of 19.33 is 45% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Asymchem Laboratories Tianjin Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asymchem Laboratories Tianjin Co's current EV-to-EBITDA is 19.33, which is 46% below median its own 10-year median of 35.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asymchem Laboratories Tianjin Co stock overvalued right now?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co (ASLTY) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.63, compared to a current price of $6.37 — trading 37.6% above its estimated fair value. The current EV-to-EBITDA is 19.33, which is 46% below median its 10-year median of 35.55 and 45% above the Biotechnology industry median of 13.33. Asymchem Laboratories Tianjin Co's overall GF Score™ is 72/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Asymchem Laboratories Tianjin Co (ASLTY), the current EV-to-EBITDA is 19.33 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asymchem Laboratories Tianjin Co (ASLTY) Overvalued in 2026?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co stock appears to be overvalued.
The current stock price of $6.37 is trading 37.6% above its estimated GF Value™ of $4.63.
GuruFocus considers Asymchem Laboratories Tianjin Co to be Significantly Overvalued.
Key valuation signals for ASLTY:
EV-to-EBITDA: 19.33 (46% below median its 10-year median of 35.55)
GF Value™: $4.63 vs. price of $6.37 (37.6% above fair value)
Industry Position: 45% above the Biotechnology median (#310 of 393)
No single metric tells the full story. See the ASLTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asymchem Laboratories Tianjin Co Business Description
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focus on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
72GF Score
Get the complete analysis for ASLTY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASLTY has been successfully added to your 
